EliLilly and Co. has bought the rights to the gene's products, although any drug is probably five years away from being marketed -- if it wins approval from the U.S. Food and Drug Administration.
Amylin Pharmaceuticals , a San Diego-based biotechnology company focused on diabetes, announced that EliLilly has signed on to co-promote one of its lead drugs.
That won't stop many analysts from speculating that the real purpose of the Medco divestment is to create a massive war chest that Merck will use to buy new drugs--or perhaps to merge with another drug firm like Schering-Plough (nyse: SGP - news - people), with which it co-promotes several drugs, or EliLilly (nyse: LLY - news - people).